ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D)...
Transcript of ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D)...
![Page 1: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/1.jpg)
Alessandro Laviano, MD
The impact of malnutrition and overnutrition on cancer outcomes
ESMO Symposium “Nutrition and Cancer”(Zurich, 20-21 March 2009)
![Page 2: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/2.jpg)
OUTLINE
• Malnutrition and survival
• Malnutrition and toxicity
• Fasting and treatment toxicity
• Does “ reverse epidemiology” apply to cancer patients?
![Page 3: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/3.jpg)
Nutrition does make the difference …
• From the mid-19th to mid-20th century, mortality ↓↓↓↓ in developed countries
• Search for historical evidence best explaining this phenomenon
• Best explaining factors: improved nutritionand immunological resistance
• Medicine largely irrelevant because effective interventions appeared only after mortality rates had already fallen substantiallyMc Keown T et al. Popul Stud (Camb) 1975; 29:391-422Birn A-E. Lancet 2005; 366:514-519
![Page 4: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/4.jpg)
![Page 5: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/5.jpg)
Effect of WL on median survival (wk)
DeWys WD et al.Prognostic effect of weight loss prior to chemotherapy in cancer patientsAm J Med 69:491-7, 1980Tumor No WL 0-5% WL 5-10% WL >10% WL pNSCL 20 17 13 11 <0.01Prostate 46 30 18 9 <0.05Colorectal 43 27 15 20 <0.01
![Page 6: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/6.jpg)
Is malnutrition still a risk factor of postoperative complicationsin gastric cancer surgery?
“The present study suggests that weight loss and hypoalbuminemia are not associated with an increased risk of mortality and morbidity in patients who underwent surgery for gastric cancer. This study may represent a stimulus for further studies aiming at evaluating the actual role of malnutrition in the development of postoperative complications in major abdominal surgery.” Pacelli F et al. Clin Nutr 2008
![Page 7: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/7.jpg)
Andreyev HJN et al. Eur J Cancer 1998
![Page 8: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/8.jpg)
Andreyev HJN et al. Eur J Cancer 1998
![Page 9: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/9.jpg)
Andreyev HJN et al. Eur J Cancer 1998
![Page 10: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/10.jpg)
Tewari N et al. Lung Cancer 2007; 57:389-94
![Page 11: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/11.jpg)
Cachexia Worsens Prognosis in Patients with ResectablePancreatic Cancer
Bachmann J et al. J Gastrointest Surg 2008
![Page 12: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/12.jpg)
Cachexia Worsens Prognosis in Patients with ResectablePancreatic Cancer
Bachmann J et al. J Gastrointest Surg 2008
![Page 13: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/13.jpg)
Meyhardt JA et al. J Clin Oncol 2004
![Page 14: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/14.jpg)
Meyhardt JA et al. J Clin Oncol 2004
![Page 15: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/15.jpg)
Meyhardt JA et al. J Clin Oncol 2004
![Page 16: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/16.jpg)
J Clin Oncol 2005
![Page 17: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/17.jpg)
no (r
efer
ence
)inc
reas
ed yes
don't
know
miss
ing
0
2
4
6
8
10
12
1
n: 5334 1328 5698 1149 2781
Odd
s ra
tio d
eath
hos
p30
(CI 9
5)
norm
al (re
fere
nce)
a bit
less
less t
han
half
less t
han
quar
ter
miss
ing
0
2
4
6
8
10
12
1
n: 6281 3130 1978 1484 3417
Odd
s ra
tio d
eath
hos
p30
(CI 9
5)
Have you lost weight unintentionally How well have you eaten within the last 3 months? during the last week?
Hiesmayr M et al. Lancet (submitted)
![Page 18: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/18.jpg)
tumor growth ↑ CKPeripheral tissue↑ ACh, NA, 5HT innervationBrainstemvagus nerve
↑ POMC → CKHypothalamus
5HT↓ NPY
↑ MCoA ← ↓FA oxidation↓ CPT1c
↑catabolism↑ energy expenditure ↑APP
↑UCPssympathetic outflow↓ food intake
Laviano A et al. Am J Physiol Endocrinol Metab 2008
![Page 19: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/19.jpg)
Andreyev HJN et al. Eur J Cancer 1998
![Page 20: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/20.jpg)
G. Reni (1575-1642)
![Page 21: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/21.jpg)
![Page 22: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/22.jpg)
PNAS 2008
![Page 23: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/23.jpg)
![Page 24: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/24.jpg)
![Page 25: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/25.jpg)
![Page 26: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/26.jpg)
Effect of population trends in BMI on prostate canc er incidence and mortality in the US
• Obesity is associated with increased risk of high-grade prostate cancer and prostate cancer mortality, and it is thus likely that the increase in obesity has increased the burden of prostate cancer.
• The predicted increase in obesity prevalence since 1980 increased high-grade prostate cancer incidence by 15.5% and prostate cancer mortality by between 7.0% (under identical survival for obese and nonobese cases) and 23.0% (under different survival for obese and nonobese cases) in 2002.
• Increasing obesity prevalence since 1980 has partially obscured declines in prostate cancer mortality.Fesinmeyer MD et al. Cancer Epidemiol Biomarkers Prev 2009
![Page 27: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/27.jpg)
Obesity as an Adverse Prognostic Factor for Patients ReceivingAdjuvant Chemotherapy for Breast Cancer
Bastarrachea J et al. Ann Intern Med 1994
![Page 28: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/28.jpg)
Obesity as an Adverse Prognostic Factor for Patients ReceivingAdjuvant Chemotherapy for Breast Cancer
Bastarrachea J et al. Ann Intern Med 1994
![Page 29: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/29.jpg)
Meyhardt JA et al. Cancer 2003
![Page 30: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/30.jpg)
Meyhardt JA et al. Cancer 2003
![Page 31: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/31.jpg)
Meyhardt JA et al. Cancer 2003
![Page 32: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/32.jpg)
J Natl Cancer Inst 2006
![Page 33: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/33.jpg)
J Natl Cancer Inst 2006
![Page 34: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/34.jpg)
Influence of obesity on cancer-related outcomes aft er pancreatectomy to treat pancreatic adenocarcinoma
• Two hundred eighty-five consecutive patients with data available for BMI calculation who underwent potentially curative pancreas resection to treat adenocarcinoma from January 1, 1999, to October 31, 2006.
• Influence of BMI and other known prognostic variables on the incidence of lymph node metastasis and disease-free and overall survival.
• Obese patients (BMI >35) were at 12-fold risk of lymph node metastasis compared with nonobese patients (BMI < or =35). The estimated disease-free and overall survival rates were decreased in the obese patients, and the risk of cancer recurrence and death after pancreatectomy was nearly twice that in nonobese patients.
• Data suggest that the negative influence of BMI of more than 35 on cancer-related end points is unrelated to the potential complexity of performing major oncologic surgery in obese patients. Fleming JB et al. Arch Surg 2009
![Page 35: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/35.jpg)
Multiple secretoryproducts
Liver
Pancreas
Muscle
Vasculature
Current View: secretory/endocrine organOld View: inert storage depot
Fatty acids Glucose
Fatty acids Glycerol
Fed
Fasted
TgTg
Tg
Lyon CJ et al 2003
![Page 36: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/36.jpg)
Adverse metabolic effects of products of adipocytes
Adiposetissue
↑ IL-6
↓ Adiponectin
↑ Leptin
↑ TNFα↑ Adipsin(Complement D) ↑ Plasminogen
activator inhibitor-1(PAI-1)
↑ Resistin
↑ FFA
↑ Insulin
↑ Agiotensinogen
↑ Lipoprotein lipase
↑ Lactate
Inflammation
Type2 diabetes
Hypertension
Atherogenicdyslipidaemia
ThrombosisAtherosclerosis Lyon 2003; Trayhurn et al 2004; Eckel et al 2005
![Page 37: ESMO Symposium on Cancer and Nutrition 2009 Presentation ... · Leptin TNF Adipsin (Complement D) Plasminogen activator inhibitor-1 (PAI-1) Resistin FFA Insulin Agiotensinogen Lipoprotein](https://reader034.fdocuments.in/reader034/viewer/2022042323/5f0df6ca7e708231d43cf314/html5/thumbnails/37.jpg)
ConclusionsConclusions• Malnutrition remains a negative prognostic factor for
cancer patients
• The increasing prevalence of obesity has offset in part the reduction of cancer mortality.
• Limited “reverse epidemiology” for obese cancer patients
• The mechanisms by which malnutrition and overnutrition impact on cancer outcomes are many, including reduced tolerance/response to therapy and corroboration of cancer-induced metabolic alterations.